New opportunities to connect at EPSRC’s Partnership Summit
This piece was written by our Director, Professor Paul Matthews.
Leaders from UKRI, universities, research institutes and industry met earlier this month at EPSRC’s Partnership Summit in Cardiff, bringing energy and candour to discussions concerning challenges faced by EPSRC and those funded by it. I had gone with full understanding of the economic pressures facing the government and UKRI. I came away with the genuinely positive sense that UK science has both the ideas, talent and ambition to shape a brighter future and the will to support them.
However, everyone sensed the urgency to achieve more with a science budget that is constrained. The financial pressures are real. Research competes for public investment with health, welfare and defense. We cannot assume that the case for science will make itself. But there was a strong undercurrent of optimism; there was a shared belief that discovery has and will create value that will be recognised. The challenge is to turn our strengths into important new knowledge, to improve lives and support growth in ways that the government and the public can see.
We need to seize the opportunity to connect ambitious discovery with problems that matter. Our research creates capabilities that allow us to ask questions that previously were difficult or impossible to ask. What we need to do is be precise about these, prioritise them jointly with stakeholders and then serially focus on realizing solutions that lead to innovation that matters. In early drug development, for example, we need to join with pharma experts to seriously ask how advanced imaging, chemical engineering of biology and AI remove uncertainty at earliest stages of development to accelerate more confident decisions.
We must not be discouraged by the need to take on big questions! If the questions are important, even partial answers can provide routes to impact. Each also opens new scientific challenges and opportunities. For example, in asking why a promising drug candidate fails to reach its target, even a partial answer showing that a compound becomes trapped in lysosomes rather than reaching its intended target, would accelerate its redesign or – if that proves too difficult- lead to an early pivot to an alternative.
Such a finding also would open new scientific questions: which molecular properties control intracellular distribution, how does this vary between cell types and could lysosomal accumulation itself be exploited therapeutically? We do not need a complete understanding of intracellular drug transport to improve a development decision. But this observation would highlight how important the intracellular biodistribution is potentially is. The discovery to translation path works in both directions: developing a better understanding of practical problems for the molecule would stimulate new discovery of fundamental mechanisms of biodistribution. This would inform better molecule design. And around it would go!
We can leverage greater impact from our capabilities through partnerships and collaboration. The life sciences pose huge challenges. We could never grow the Institute to the point that its scientists could provide all the insights, technologies or connections needed. We need to seek considerable support for this externally. The Franklin’s relationships with our founder universities and other research organisations provide a powerful starting point. Academic or local facility partnerships strengthen our discovery capabilities. Stronger industry partnerships can help us identify the problems where our science could make the greatest difference and create routes for putting discoveries to work.
The growing emphasis on regional partnerships with the new government adds another opportunity. Complementary facilities, expertise and businesses offer exceptional scope for joint programmes at Harwell. We should take a lead in helping to shape those programmes around prioritised discovery and translational ambitions. This will create the kind of virtual organisation that is needed to ask and solve big questions. Strengthening the science and infrastructure also will help the community around us grow with new investment and new jobs.
At the same time, we need to be constantly reviewing how we are doing this. For example, AI is fundamentally reshaping how science is done. In the Franklin, we need to think together to develop an active strategy for realising the benefits of this powerful technology, as well as avoiding its risks. We need to decide where it can most improve our experiments, interpretation and productivity, then develop the skills and partnerships to use it effectively. Our agility is a major advantage if we move with purpose.
Pursuing discovery with an eye to translation, developing partnerships and harnessing AI should be exciting for all of us. We also need to help the public become equally as excited! We are expecting the public to fund our work. We therefore need to make the connections between our science and its benefits to the public clear.
I left the summit optimistic. Across the research community, I saw a willingness to collaborate and a commitment to keeping science central to the UK’s future. For the Franklin, the task is clear: pursue bold discovery, build purposeful partnerships and demonstrate what they make possible. We have an opportunity to shape the future of research and the benefits it delivers. We should seize it.